Global Orthobiologics Market - Snapshot

Orthobiologics comprise tissue and bone replacement materials used for quick recovery of ligaments, tendons, muscles, and broken bones. The global orthobiologics market was valued at US$ 4.8 Bn in 2017 and is projected to reach US$ 7.9 Bn by 2026 at a CAGR of 5.5% from 2018 to 2026. Rise in prevalence of chronic arthritis and increase in the geriatric population are anticipated to drive the global market. Additionally, increase in demand for biologics in minimally invasive procedures and rise in patient awareness are expected to propel the global market. Surge in sports injuries is expected to augment the global orthobiologics market. However, orthobiologics are relatively new; hence, reimbursement is less. This is likely to restrain the global market. According to the U.S. Department of Health and Human Services, 2 million people in the U.S. suffer from sports injuries each year. According to Spinal Cord, Inc., the U.S. had 245,000 to 353,000 people living with spinal cord injury in 2017. Furthermore, stringent regulatory requirements is projected to restrain the global orthobiologics market.

global orthobiologics market

In terms of product, the global orthobiologics market has been categorized into bone morphogenetic proteins, demineralized bone matrix, synthetic bone substitutes, viscosupplements, allografts, stem cell, and others. The viscosupplements segment dominated the market in 2017 due to rise in prevalence of knee osteoarthritis. Based on application, the market has been classified into spinal fusion, trauma repair, reconstructive surgeries, and others. The spinal fusion segment accounted for the largest share of the market in 2017 owing to rise in prevalence of spine and traumatic injuries, sports-related injuries, and accidents. In terms of end-user, the global orthobiologics market has been classified into hospitals, orthopedic clinics, and others. Increase in incidence of orthopedic injuries, nerve & tendon injuries, sports injuries, and accident injuries is anticipated to drive the hospitals segment.

In terms of region, the global orthobiologics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for major share of the market in 2017. Emerging technologies in orthobiologics is anticipated to drive the market in the region during the forecast period. Additionally, rise in prevalence of sports-related injuries and injuries caused due to falls & accidents propel the market in the region. Rise in prevalence of sports injuries, increase in orthopedic procedures, and surge in the geriatric population in China, India, and Australia are anticipated to augment the market in Asia Pacific. Increase in the geriatric population is expected to drive the market in Middle East & Africa.

Major players operating in the global orthobiologics market include Medtronic, DePuy Synthes (Johnson & Johnson), Sanofi, Seikagaku Corporation, Stryker, MTF Biologics, Bioventus LLC, Arthrex, Zimmer Biomet, RTI Surgical, Inc., Alphatec Spine, Inc., Exactech, Inc., Globus Medical, Inc., and Integra LifeSciences. Focus on emerging technologies and increase in trend of mergers and acquisitions are expected to boost the global market during the forecast period. In September 2018, NuVasive, Inc. launched a product line for Propel DBM. The Propel DBM product line includes gel, gel plus, and putty plus. To broaden the product line, the company provides Propel DBM gel and Propel DBM Putty with osteoconductive property which help to promote bone growth. In March 2018, Synergy Biomedical LLC received clearance from Therapeutic Goods Clearance (TGA) in Australia for BioSphere Putty, a synthetic bone graft product that helps bone healing.

Global Orthobiologics Market: Overview 

This report analyzes the current and future scenario of the global orthobiologics market. Surge in the number of orthopedic procedures, increase in demand for biologics in spinal surgery and traumatic injuries, and rise in prevalence of chronic arthritis are projected to drive the global market. Additionally, rise in prevalence of sports injuries propels the global orthobiologics market.

This report comprises an elaborate executive summary, which includes information about various segments of the global orthobiologics market. It also provides information and data analysis of the global market with respect to the segments based on product, application, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global orthobiologics market. 

Global Orthobiologics Market: Key Segments

In terms of product, the global orthobiologics market has been segmented into bone morphogenetic proteins, demineralized bone matrix, synthetic bone substitutes, viscosupplements, allografts, stem cell, and others. Based on application, the global market has been classified into spinal fusion, trauma repair, reconstructive surgeries, and others. In terms of end-user, the global orthobiologics market has been segmented into hospitals, orthopedic clinics, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Orthobiologics Market: Regional Outlook

In terms of region, the global orthobiologics market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

The report also profiles major players in the global orthobiologics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in the report include Medtronic, DePuy Synthes (Johnson & Johnson), Sanofi, Seikagaku Corporation, Stryker, MTF Biologics, Bioventus, Arthrex, Zimmer Biomet, RTI Surgical, Inc., Alphatec Spine, Inc., Exactech, Inc., Globus Medical, Inc., and Integra LifeSciences. 

The global orthobiologics market has been segmented as below:           

  • Global Orthobiologics Market, by Product
    • Bone Morphogenetic Proteins
    • Demineralized Bone Matrix
    • Synthetic Bone Substitutes
    • Viscosupplements
    • Allografts
    • Stem cell
    • Others
       
  • Global Orthobiologics Market, by Application
    • Spinal Fusion
    • Trauma Repair
    • Reconstructive Surgeries
    • Others
       
  • Global Orthobiologics Market, by End-user
    • Hospitals
    • Orthopedic Clinics
    • Others
       
  • Global Orthobiologics Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • Italy
      • France
      • Spain
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Israel
      • Rest of Middle East & Africa
.